Gainers:
Children's Place Retail Stores, Inc. (PLCE) is rising nearly 5 percent to $54.00. The company's second quarter loss widened from the year-ago quarter, but was lesser than what analysts' had estimated. Net sales increased 5 percent and topped the consensus estimate. However, the company forecast third quarter non-GAAP adjusted earnings per share below Wall Street view. The company raised the lower end of its fiscal 2012 non-GAAP adjusted earnings per share guidance range.
Sears Holdings Corp. (SHLD) is gaining 4 percent to $58.81. The company's second quarter loss narrowed from the same period a year earlier. Domestic comparable store sales declined 3.7 percent, with declines of 2.9 percent at Sears Domestic and 4.7 percent at Kmart.
Best Buy Co. Inc. (BBY) is rising more than 2 percent to $19.90 based on the news that its founder Richard Schulze has sent a letter to the company's board requesting permission to form a group and conduct basic due diligence so that he can present a fully financed offer for the company.
CompuCredit Holdings Corp. (CCRT) is jumping 59 percent to $8.00. The company announced that it has commenced a cash tender offer for up to 8.25 million common shares at $10.00 per share.
Cisco Systems, Inc. (CSCO) is rising 7 percent to $18.59 following the release of its fourth quarter results.
Decliners:
Wal-Mart Stores Inc. (WMT) is falling over 2 percent to $72.70. The company's second quarter profit and net sales increased from the same period last year. Walmart U.S. comparable store sales rose 2.2 percent. The company also raised its full-year earnings per share guidance.
Dollar Tree, Inc. (DLTR) is declining 6 percent to $46.92. The company's second quarter profit improved from the last year quarter and was above analysts' estimate. Comparable store sales for the quarter rose 4.5 percent. However, the company guided third quarter results below analysts' expectations.
Trading halt:
Trading in shares of Idenix Pharmaceuticals Inc. (IDIX) was halted. The company announced that it has received verbal notice from the U.S. FDA that a partial clinical hold has been placed on IDX184, its nucleotide polymerase inhibitor under development for the treatment of hepatitis C virus.
For comments and feedback: editorial@rttnews.com